Long-term value creation in the pharmaceutical sector: an event study analysis of big pharma stocks Online publication date: Fri, 21-Nov-2014
by Andrija Tomovic; Erdal Atukeren
International Journal of Sustainable Economy (IJSE), Vol. 4, No. 4, 2012
Abstract: We investigate the drivers of value creation in big pharmaceutical firms. We use a unique dataset of a total of 2,200 news items on research and development (R&D) progress announcements and dividend news of 25 largest pharmaceutical companies for the period 1998-2010. Our findings affirm the role of successful R&D as a driver of value creation in the long-run. This long term view of value creation has implications for sustainability. R&D is a critical input to long-term sustainable growth and the pharmaceutical sector is one of the highest R&D-intense sectors. Furthermore, successful R&D leading to the discovery of new drugs enhances the prospects for a sustainable economy by improving the society's health status and well-being. Indeed, we find that negative R&D news destroys more long-term value than the value created by positive news. This highlights the concern for the overall long-term adverse implications of unsuccessful R&D on the economy.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Sustainable Economy (IJSE):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook